FDA approve first biologic drug for use in patients with non-radiographic Axial Spondyloarthritis

NEWSFLASH!

On March 28, 2019 the U.S. Food and Drug Administration approved certolizumab pegol (Cimzia®) for use in patients with non-radiographic Axial Spondyloarthritis. It is the first time that a biologic drug has been approved for nrAxSpA.

Read the full FDA press release

Other NEWS

ASIF name change

At the recent AGM, members voted to change the name of ASIF to:

Read More